Background: To evaluate the effect of tissue inhibitor of metalloproteinase-1 small interfering RNA (TIMP-1 siRNA) transfected fibroblasts (FB) for urethral reconstruction. Materials and Methods: A ventral urethral mucosal defect was created. Substitution urethroplasty was performed with small intestinal submucosa (SIS) alone (8 rabbits, group 1), autogenic oral keratinocytes (OK)-seeded SIS (8 rabbits, group 2) or autogenic OK and TIMP-1 siRNA transfected FB-seeded SIS (8 rabbits, group 3). At 1 and 6 months after surgery (4 rabbits at each time point), retrograde urethrogram and histologic analysis were performed to evaluate the outcomes of urethroplasty. Results: TIMP-1 siRNA transfected FB decreased the secretion of type I collagen. Under retrograde urethrography, 5 rabbits in group 1, 6 in group 2 and 7 in group 3 maintained a wide urethral caliber. Histologically, inflammation and fibrosis were observed at 6 months in group 1. The speed of urothelium, smooth muscle and vessel regeneration in group 3 was faster than that in group 2. Comparison of smooth muscle-to-collagen ratio, epithelial layers, smooth muscle content and microvessel density among three groups revealed a significant increase (p < 0.05). Conclusions: TIMP-1 siRNA transfected FB could be used as a source of seed cell for urethral tissue engineering and could prevent the proliferation of urethral scar tissue.

Keywords:
Tissue engineering, Tissue inhibitor of metalloproteinase-1 , Small intestinal submucosa, Oral keratinocytes, Fibroblasts, Urethral reconstruction
1.
Xu Y, Qiao Y, Sa Y, et al: An experimental study of colonic mucosal graft for urethral reconstruction. Chin Med J (Engl) 2002;115:1163-1165.
2.
Xu YM, Sa YL, Qiao Y, et al: Histopathological changes of free buccal mucosa and colonic mucosa grafts after translation to dog bladder. Chin Med J (Engl) 2005;118:337-339.
3.
Song LJ, Xu YM, Hu XY, et al: Urethral substitution using autologous lingual mucosal grafts: an experimental study. BJU Int 2008;101:739-743.
4.
Ding J, Li Q, Li S, et al: Ten years' experience for hypospadias repair: combined buccal mucosa graft and local flap for urethral reconstruction. Urol Int 2014;93:454-459.
5.
Thiry S, Saussez T, Dormeus S, et al: Long-term functional, cosmetic and sexual outcomes of hypospadias correction performed in childhood. Urol Int 2015;95:137-141.
6.
Jang TL, Erickson B, Medendorp A, et al: Comparison of donor site intraoral morbidity after mucosal graft harvesting for urethral reconstruction. Urology 2005;66:716-720.
7.
Kropp BP, Ludlow JK, Spicer D, et al: Rabbit urethral regeneration using small intestinal submucosa onlay grafts. Urology 1998;52:138-142.
8.
Fiala R, Vidlar A, Vrtal R, et al: Porcine small intestinal submucosa graft for repair of anterior urethral strictures. Eur Urol 2007;51:1702-1708; discussion 1708.
9.
Li C, Xu YM, Liu ZS, et al: Urethral reconstruction with tissue engineering and RNA interference techniques in rabbits. Urology 2013;81:1075-1080.
10.
Xie M, Xu Y, Song L, et al: Tissue-engineered buccal mucosa using silk fibroin matrices for urethral reconstruction in a canine model. J Surg Res 2014;188:1-7.
11.
Huang X, Wei DP, Yang YR: [Detection of collagenase activity and tissue inhibitor of metalloproteinase-1 expression level in the urethral scar tissue]. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi 2003;17:433-435.
12.
Chen B, Wen Y, Wang H, et al: Differences in estrogen modulation of tissue inhibitor of matrix metalloproteinase-1 and matrix metalloproteinase-1 expression in cultured fibroblasts from continent and incontinent women. Am J Obstet Gynecol 2003;189:59-65.
13.
Sa Y, Li C, Li H, et al: TIMP-1 induces α-smooth muscle actin in fibroblasts to promote urethral scar formation. Cell Physiol Biochem 2015;35:2233-2243.
14.
Aoki M, Miyake K, Ogawa R, et al: siRNA knockdown of tissue inhibitor of metalloproteinase-1 in keloid fibroblasts leads to degradation of collagen type I. J Invest Dermatol 2014;134:818-826.
15.
Djafarzadeh R, Notohamiprodjo S, Rieth N, et al: Treatment of dermal fibroblasts with GPI-anchored human TIMP-1 protein moderates processes linked to scar formation. J Invest Dermatol 2013;133:803-811.
16.
Simon F, Bergeron D, Larochelle S, et al: Enhanced secretion of TIMP-1 by human hypertrophic scar keratinocytes could contribute to fibrosis. Burns 2012;38:421-427.
17.
Ruiter D, Bogenrieder T, Elder D, et al: Melanoma-stroma interactions: structural and functional aspects. Lancet Oncol 2002;3:35-43.
18.
Luo JC, Chen W, Chen XH, et al: A multi-step method for preparation of porcine small intestinal submucosa (SIS). Biomaterials 2011;32:706-713.
19.
Reynolds A, Leake D, Boese Q, et al: Rational siRNA design for RNA interference. Nat Biotechnol 2004;22:326-330.
20.
Egea V, Zahler S, Rieth N, et al: Tissue inhibitor of metalloproteinase-1 (TIMP-1) regulates mesenchymal stem cells through let-7f microRNA and Wnt/β-catenin signaling. Proc Natl Acad Sci U S A 2012;109:E309-E316.
21.
Orabi H, Aboushwareb T, Zhang Y, et al: Cell-seeded tubularized scaffolds for reconstruction of long urethral defects: a preclinical study. Eur Urol 2013;63:531-538.
22.
Bhargava S, Patterson JM, Inman RD, et al: Tissue-engineered buccal mucosa urethroplasty-clinical outcomes. Eur Urol 2008;53:1263-1269.
23.
Bhargava S, Chapple CR: Buccal mucosal urethroplasty: is it the new gold standard? BJU Int 2004;93:1191-1193.
24.
Kimball JR, Nittayananta W, Klausner M, et al: Antimicrobial barrier of an in vitro oral epithelial model. Arch Oral Biol 2006;51:775-783.
25.
Liu Y, Luo H, Wang X, et al: In vitro construction of scaffold-free bilayered tissue-engineered skin containing capillary networks. Biomed Res Int 2013;2013:561410.
© 2015 S. Karger AG, Basel
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.